These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21334525)

  • 1. Paricalcitol for reduction of albuminuria in diabetes.
    Ortiz A; Sanchez Niño MD; Rojas J; Egido J
    Lancet; 2011 Feb; 377(9766):635-6, author reply 636-7. PubMed ID: 21334525
    [No Abstract]   [Full Text] [Related]  

  • 2. Paricalcitol for reduction of albuminuria in diabetes.
    Delanaye P; Mariat C; Krzesinski JM; Cavalier E
    Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334526
    [No Abstract]   [Full Text] [Related]  

  • 3. Paricalcitol for reduction of albuminuria in diabetes.
    Fourtounas C
    Lancet; 2011 Feb; 377(9766):636, author reply 636-7. PubMed ID: 21334527
    [No Abstract]   [Full Text] [Related]  

  • 4. Paricalcitol for reduction of albuminuria in diabetes.
    Kassimatis T
    Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334524
    [No Abstract]   [Full Text] [Related]  

  • 5. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
    Kröpelin TF; de Zeeuw D; Andress DL; Bijlsma MJ; Persson F; Parving HH; Heerspink HJ
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):410-6. PubMed ID: 25568217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
    de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
    Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
    Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New clinical trials with vitamin D and analogs in renal disease.
    Kumar R
    Kidney Int; 2011 Oct; 80(8):793-6. PubMed ID: 21832981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients.
    Ekart R; Bevc S; Hojs R; Hojs N
    J Clin Pharmacol; 2016 Jun; 56(6):761-8. PubMed ID: 26465921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
    Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
    G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
    Duplancic D; Cesarik M; Poljak NK; Radman M; Kovacic V; Radic J; Rogosic V
    Clin Interv Aging; 2013; 8():149-56. PubMed ID: 23430986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
    Bellasi A; Galassi A; Salvi P; Cozzolino M
    Blood Purif; 2013; 36(1):12-6. PubMed ID: 23736115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Into the light? Diabetic nephropathy and vitamin D.
    Thomas MC; Cooper ME
    Lancet; 2010 Nov; 376(9752):1521-2. PubMed ID: 21055802
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years.
    Pietras SM; Obayan BK; Cai MH; Holick MF
    Arch Intern Med; 2009 Oct; 169(19):1806-8. PubMed ID: 19858440
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
    Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
    [No Abstract]   [Full Text] [Related]  

  • 17. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
    Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature.
    Schuster A; Al-Makki A; Shepler B
    Clin Ther; 2019 Nov; 41(11):2416-2423. PubMed ID: 31601446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.
    Lambers Heerspink HJ; Agarwal R; Coyne DW; Parving HH; Ritz E; Remuzzi G; Audhya P; Amdahl MJ; Andress DL; de Zeeuw D
    Am J Nephrol; 2009; 30(3):280-6. PubMed ID: 19521070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.